Retinoids were studied both to identify what skeletal components are important in the modulation of normal and leukemic human myeloid clonal proliferation and differentiation in vitro and to elucidate the mechanism by which retinoids modulate proliferation of hematopoietic cells. Retinoids with a derivatized terminal carboxyl group were significantly less active than all-transretinoic acid, and those with the addition of two methyl groups to the cyclohexenyl ring of retinoic acid or substitution of its 
eficial effect on hematopoiesis in patients with the myelodysplastic syndrome (5).
A new generation of retinoids has been synthesized that differs at their ring, side-chain, and polar functional units. We utilized all-trans-retinoic acid and these new retinoids in order: (a) to explore the importance of the influence of various structural modifications of the retinoid skeleton on normal and leukemic myeloid clonal proliferation and differentiation in vitro; and (b) to attempt to elucidate the mechanism of action of retinoids on the proliferation of normal and neoplastic hematopoietic cells.
Methods
Retinoids. The structure of the retinoids used in these experiments is shown in Table I . All-trans-retinoic acid (No. 1), Cells. The human myeloid leukemia cell lines HL-60 and KG-1, and the murine myeloid leukemia cell line Ml were maintained in suspension culture in T flasks (Miles Laboratories, Inc., Naperville, IL) containing alpha modified minimum essential medium (Flow Laboratories, Inc., McLean, VA) and 10% fetal calf serum (FCS;' Irvine Scientific, Santa Ana, CA). The cells were incubated in a humidified atmosphere containing 7% CO2. The medium was changed twice weekly. The HL-60 cell line is predominantly blocked at the promyelocytic stage (6) and the KG-I line is composed of myeloblasts (7) . The M I myeloblast line was derived originally from an SL murine myeloid leukemia (8) . All retinamide, and N-(2,3-dihydroxypropyl) retinamide were also inactive at concentrations of 10-11_lO-6 M (data not shown).
We determined whether the retinoids had a similar structureactivity relationship on the clonal growth of a less mature human No induction at 10-6 * Induction of differentiation determined by ability of cells to reduce nitroblue tetrazolium.
t All-trans-retinoic acid.
myeloid leukemia cell line, known as KG-1. These cells are at the myeloblast stage of differentiation, and early passage of the cells are unique because their clonal growth is dependent on CSF (7). The various retinoids had a structure-activity pattern with the KG-I cells that was similar to that of the clonal growth of HL-60 cells (Fig. 2) . The KG-I cells were even more sensitive than HL-60 cells to growth inhibition by the more potent analogues. For example, a 50% inhibition of growth was achieved by retinoid Nos. 3 and 4 at 3 X 10-10 and 4 X 10-10 M, respectively (Table II) . The only exception was the TTNPB analogue (No. 5), which was more inhibitory of HL-60 than KG-I clonal growth. In a pattern similar to our findings with HL-60, the compounds with a derivatized terminal carboxyl moiety were weakly active (Nos. 7 and 8) or inactive (Nos. 9 and 10) in clonal growth inhibition of KG-I cells.
We examined the ability ofthe retinoids (Nos. 1-10), (10-'°-10-6 M) to affect the clonal growth ofthe Ml murine myeloblast cell line. This cell line is induced to differentiate by a wide variety of compounds (14) . We found that only high concentrations
(1 X 10-6 M) of the indanyl analogue of retinoic acid (No. 2) inhibited clonal growth (26%) as compared with control plates containing no retinoid. All other retinoids (<10-6 M) had no effect on clonal growth of MI cells. We studied the potency of different retinoids (Nos. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] over a wide range of concentrations (10-0_10-6 M) to induce differentiation of HL-60 cells as assessed by the ability of the cells to reduce NBT. Table II 4 (which differs from all-trans-retinoic acid by the addition of two methyl groups) (Fig. 3) . This combination additively inhibited clonal growth of HL-60 cells at each concentration of the compounds tested (10-"-l0-9 M).
Effect of retinoids on clonal proliferation of normal human myeloid stem cells. We studied the effect of retinoids (Nos. 1-10) on the clonal growth of normal human myeloid progenitor cells (GM-CFC). We found that retinoids Nos. 1-8 had a 1.5-2.1-fold stimulatory effect on GM-CFC formation in the presence of a submaximal stimulating concentration of CSF (Fig. 4) . The addition of analogues with a free carboxyl group (Nos. 1-6) to the culture plates markedly increased the formation of myeloid colonies. These compounds achieved a maximal enhancement at 1 X 10-7 M, increasing the number of GM-CFC in the range of 155-208% as compared with plates not containing a retinoid.
The concentration of the ethyl ester retinoids (Nos. 7 and 8) required to maximally enhance the formation of normal human myeloid colonies was -10-100-fold higher (1 X 10-6 M) than that for the compounds with a terminal carboxyl group. At this concentration, the most potent analogues (Nos. 1-5) became less active, probably because oftoxic effects. At 1 X 10-5 M, all retinoids inhibited GM-CFC formation. The amide derivatives (Nos. 9 and 10) showed no stimulation of normal human progenitor cells. Table III Retinoid (M) Figure 3 . 120±8 (±SD) colonies.) We subjected the data to an analysis ofvariants which showed that the combination of the two agents had neither an additive effect (P < 0.001) nor the same effect (P < 0.001) as each agent alone.
Mechanism ofstimulation ofGM-CFC by retinoids. We performed a series of experiments in an attempt to elucidate how the various retinoids might enhance clonal growth of normal human GM-CSF. One possibility is that the retinoids stimulate an accessory marrow cell to synthesize CSF. To test this hypothesis, we incubated bone marrow cells in liquid culture for 5 d with the potent retinoid No. 2 (1-0 M) and harvested the CM. The CM was exposed for 3 h to bright sunlight, which abolished the activity of the retinoid, and then was tested for CSF activity. No difference in number of GM-CFC occurred between culture plates containing CM of marrow cells exposed to retinoid No. 2 (mean 5.5±0.8 [±SD] ) and control plates (mean 5.25±0. 9 [±SD]) containing CM of marrow cells which were not exposed to a retinoid. Positive control plates, to which 1.5% CSF-rich CM was added, contained a mean 45.8±5 (±SD) GM-CFC.
We further studied the retinoid-mediated enhancement of myeloid clonal growth by performing CSF dose-response experiments in the presence ofthe maximally stimulating concentration of retinoid No. 4 (10-7 M) (Fig. 5) . No GM-CFC formation could be observed in plates containing No. 4 alone, indicating that the compound is not by itself a growth factor for myeloid stem cells. However, in the presence of increasing concentrations ofCSF, plates containing the retinoid had an -1.8- either recombinant GM-CSF (dilution of 1:8,000) or partially purified GCT-CSF (20 ul/ml). Again, the retinoid continued to enhance colony formation. Mean values were 170%±22 (±SD) and 180%±25 (±SD) compared with control plates containing the maximally stimulating concentrations of CSF alone.
Discussion
Our data defined the structure-activity relationship of 10 retinoids as measured by clonal growth inhibition ofthe HL-60 and KG-I human myeloid cell lines. We found that retinoic acid derivatives with a carboxyl group were significantly more active than retinoids with a derivatized carboxyl moiety. Strickland et al. (15) recently emphasized the importance ofthe terminal carboxyl group in experiments that tested the ability of benzoic acid derivatives of retinoic acid to induce differentiation of HL-60 cells and murine F9 teratocarcinoma cells. Replacing the terminal acid group of TTNPB by hydrogen decreased activity with HL-60 cells by at least 10-fold. Increasing alkyl group substitution on the lipophilic head of the retinoid skeleton also enhanced activity. We found that the addition of two geminal methyl groups to the cyclohexenyl ring ofall-trans-retinoic acid at position 3 or 4 increased the clonal leukemic cell inhibitory activity -10-fold. Also, these retinoids were more potent than TTNPB, suggesting that the replacement ofthe 1 1E, 1 3E-double bond system by a benzene ring does not enhance biological activity in these systems. This finding is supported by the lower ED50 values found for retinoid No. 2 compared with No. 5. We observed a similar structure-activity relationship between the retinoids in their growth inhibition of two human leukemic cell lines, HL-60 and KG-1. This suggests a common structural requirement for inhibition of human myeloid leukemic cells, even though the cells are blocked at different stages of differentiation and have different responsiveness to CSF (16) . The potency of the retinoids to induce differentiation of HL-60 generally paralleled the ability ofthese compounds to inhibit clonal growth of both KG-I and HL-60 cells. In contrast, the myeloblastic KG-I cells could not be induced to undergo differentiation by the retinoids. Taken together, our data show that certain retinoids are potent inhibitors of leukemic cell proliferation without necessarily inducing differentiation of the cells.
The inhibition of growth of leukemic cells by the retinoids is unlikely to be merely a "toxic" effect for several reasons: (a) Very low concentrations of the potent retinoids (Nos. 1-6) markedly inhibited clonal growth (ED50 3 X 10-'°-2.0 X 10-8 M). (b) These concentrations of the retinoids had little effect on the clonal growth ofthe murine myeloid leukemia cell line, M 1. (c) The same concentrations of these retinoids that inhibited leukemic colony formation markedly stimulated normal human myeloid colony formation.
Retinamides, the amide derivatives of all-trans-retinoic acid, are of interest because they have reduced toxicity in animal models, but nevertheless retain their high biological activity in these models (17) (18) (19) . Retinamides inhibit chemically-induced carcinogenesis in the mammary gland and urinary bladder of experimental animals (19-21) and reverse epithelial keratinization of hamster trachea (22, 23) . We found that retinamides had no activity on HL-60, KG-1, and normal human GM-CFC. This inactivity could be explained by the absence ofthe necessary metabolizing systems in normal and leukemic human hematopoietic cells. Probably, as a class, retinamides must be converted to retinoic acid to be active, and perhaps human hematopoietic cells cannot metabolize retinamides to retinoic acid.
Previously, we showed that all-trans-retinoic acid enhanced the in vitro growth of normal myeloid progenitor cells (2) . Our present study shows a relationship between retinoid structure and the ability of the compound to stimulate normal myeloid colony formation. Furthermore, we observed a parallel potency of the various retinoids both in stimulating normal myeloid clonal growth and in inhibiting leukemic myeloid clonal growth. These findings suggest, but do not prove, that certain common structural moieties of the retinoids are important in the modulation of both normal and abnormal hematopoiesis. For example, the terminal carboxyl moiety is the most important structure for both the inhibitory and the stimulatory activities. Changes in ring structure (substitution ofthe ,B-cyclogeranylidene group with a 1, 1,3,3-5-indanyl ring system) and side-chain (addition of two methyl groups to the cyclohexenyl ring) also contribute to the stimulation of normal GM-CFC and inhibition of leukemic clonogenic cells.
In a further attempt to understand how retinoids modulate hematopoietic clonal proliferation, we added in combination two potent retinoids (Nos. 2 and 4) having different ring and side-chain structures to culture plates containing either HL-60 or normal human marrow cells. The combinations of the retinoids had an additive, but not synergistic, effect on the inhibition of HL-60 clonal growth. A subadditive effect on the stimulation of normal human GM-CFC occurred when each retinoid, at its maximally stimulating concentration, was added in combination to the culture plates. Neither experimental result allows us to determine unequivocally whether structurally dissimilar retinoids act by a similar cellular pathway. A synergistic response by the combination ofretinoids with HL-60 cells would have suggested that different retinoids mediate their effects by different cellular mechanisms. Likewise, a clearly additive enhancement of GM-CFC by maximally stimulating concentrations ofboth retinoids would again have suggested that structurally different retinoids might mediate their actions by alternate cellular pathways. In contrast, although not conclusive, our data are consistent with the hypothesis that structurally dissimilar retinoids can effect hematopoietic proliferation through a common cellular pathway.
One potential common pathway of retinoid action is a binding to a cytoplasmic retinoic acid binding protein (cRABP). A positive correlation occurs between binding of some retinoids to cRABP and their biological potency in various tissues (23, 24) . The terminal carboxyl group seems to be essential for the binding ability of the retinoids to cRABP (24) . We found in previous studies that KG-1, HL-60, and acute myeloid leukemic cells harvested from patients do not possess detectable cRABP (3) . Nevertheless, the rank-order of potency of retinoid action on hematopoietic cells parallels the rank-order of potency of retinoid action on other tissues that do contain cRABP. These data may suggest that retinoids mediate their biological effects through different mechanisms in different tissue; or, also likely, that they may mediate through the same mechanism and that this mechanism is independent of cRABP.
We found that retinoids do not act by themselves as a myeloid growth factor (CSF), nor do the retinoids stimulate cells in culture to produce additional CSF. Our CSF-dose-response experiments showed that, even in the presence ofmaximally stimulating concentrations of CSF, the new retinoids enhanced normal human myeloid colony formation. These findings suggest that retinoids may either recruit earlier progenitors to become GM-CFC or that retinoids might enhance the sensitivity of normal human GM-CFC to the action of CSF, perhaps by increasing CSF receptor number or affinity on the surface of the cell. Further studies are in progress in an effort to understand the difference in response of normal and leukemic colony-forming cells to retinoids.
